Opaleye Management as of Sept. 30, 2015
Portfolio Holdings for Opaleye Management
Opaleye Management holds 49 positions in its portfolio as reported in the September 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Chimerix (CMRX) | 5.8 | $12M | 310k | 38.20 | |
| Ultragenyx Pharmaceutical (RARE) | 5.2 | $11M | 110k | 96.31 | |
| Cempra | 4.9 | $10M | 360k | 27.84 | |
| Axogen (AXGN) | 4.3 | $8.7M | 2.1M | 4.12 | |
| Medgenics | 4.1 | $8.3M | 1.1M | 7.82 | |
| AMAG Pharmaceuticals | 3.9 | $7.9M | 200k | 39.73 | |
| Imprimis Pharmaceuticals | 3.8 | $7.7M | 1.2M | 6.42 | |
| Ariad Pharmaceuticals | 3.8 | $7.7M | 1.3M | 5.84 | |
| Retrophin | 3.7 | $7.5M | 370k | 20.26 | |
| Fibrogen | 3.5 | $7.1M | 325k | 21.92 | |
| Supernus Pharmaceuticals (SUPN) | 3.2 | $6.5M | 460k | 14.03 | |
| Zs Pharma | 3.1 | $6.2M | 95k | 65.66 | |
| Inotek Pharmaceuticals Corp conv | 3.0 | $6.0M | 643k | 9.40 | |
| Cara Therapeutics | 2.9 | $5.9M | 415k | 14.29 | |
| Codexis (CDXS) | 2.7 | $5.5M | 1.6M | 3.39 | |
| Eagle Pharmaceuticals (EGRX) | 2.7 | $5.4M | 73k | 74.03 | |
| Flamel Technologies | 2.5 | $5.1M | 310k | 16.31 | |
| Geron Corporation (GERN) | 2.5 | $5.0M | 1.8M | 2.76 | |
| Neurocrine Biosciences (NBIX) | 2.5 | $5.0M | 125k | 39.78 | |
| Protalix Biotherapeutics Inc note 4.500% 9/1 | 2.1 | $4.3M | 3.6M | 1.18 | |
| Ophthotech | 2.1 | $4.3M | 105k | 40.52 | |
| Affimed Therapeutics B V | 1.8 | $3.6M | 590k | 6.17 | |
| Cytrx | 1.8 | $3.6M | 1.5M | 2.37 | |
| Intec Pharma | 1.7 | $3.5M | 630k | 5.60 | |
| Amarin Corporation | 1.7 | $3.4M | 1.8M | 1.93 | |
| Zogenix | 1.7 | $3.4M | 250k | 13.50 | |
| Trillium Therapeutics, Inc. Cmn | 1.6 | $3.2M | 245k | 13.03 | |
| Tonix Pharmaceuticls | 1.5 | $3.0M | 570k | 5.29 | |
| Blueprint Medicines (BPMC) | 1.4 | $2.8M | 130k | 21.34 | |
| Adamas Pharmaceuticals | 1.4 | $2.8M | 166k | 16.74 | |
| Momenta Pharmaceuticals | 1.3 | $2.6M | 160k | 16.41 | |
| Tg Therapeutics (TGTX) | 1.3 | $2.6M | 260k | 10.08 | |
| Agile Therapeutics | 1.3 | $2.6M | 385k | 6.74 | |
| Avinger | 1.3 | $2.6M | 175k | 14.71 | |
| Nivalis Therapeutics | 1.1 | $2.3M | 175k | 12.97 | |
| XOMA CORP Common equity shares | 1.1 | $2.2M | 3.0M | 0.75 | |
| Foamix Pharmaceuticals | 1.0 | $2.1M | 285k | 7.33 | |
| Tenax Therapeutics | 0.9 | $1.9M | 635k | 3.00 | |
| Accelr8 Technology | 0.8 | $1.5M | 95k | 16.18 | |
| Auris Med Hldg | 0.6 | $1.3M | 355k | 3.56 | |
| Xenon Pharmaceuticals (XENE) | 0.6 | $1.2M | 151k | 8.26 | |
| Sage Therapeutics (SAGE) | 0.4 | $846k | 20k | 42.30 | |
| Evoke Pharma | 0.4 | $757k | 260k | 2.91 | |
| Innocoll | 0.3 | $695k | 56k | 12.51 | |
| Celgene Corp right 12/31/2011 | 0.3 | $547k | 340k | 1.61 | |
| Alder Biopharmaceuticals | 0.3 | $527k | 16k | 32.73 | |
| Cynapsus Therapeutics | 0.2 | $469k | 29k | 16.17 | |
| Biolinerx Ltd-spons | 0.2 | $383k | 250k | 1.53 | |
| Tracon Pharmaceuticals | 0.1 | $119k | 12k | 9.78 |
